136 related articles for article (PubMed ID: 32240378)
1. Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Ida S; Kumagai K; Sano T; Nunobe S
Surg Today; 2020 Oct; 50(10):1197-1205. PubMed ID: 32240378
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy.
Shitara K; Chin K; Yoshikawa T; Katai H; Terashima M; Ito S; Hirao M; Yoshida K; Oki E; Sasako M; Emi Y; Tsujinaka T
Gastric Cancer; 2017 Jan; 20(1):175-181. PubMed ID: 26626800
[TBL] [Abstract][Full Text] [Related]
3. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
[TBL] [Abstract][Full Text] [Related]
4. [Current status of adjuvant chemotherapy in patients with p-Stage II and p-Stage III gastric cancer].
Sato Y; Yajima K; Kosugi S; Muneoka Y; Ichikawa H; Hanyu T; Sakamoto K; Ishikawa T; Wakai T
Gan To Kagaku Ryoho; 2014 Aug; 41(8):961-4. PubMed ID: 25132026
[TBL] [Abstract][Full Text] [Related]
5. Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).
Fujitani K; Tamura S; Kimura Y; Matsuyama J; Imamura H; Yamamoto K; Fujita J; Iijima S; Ueda S; Kurokawa Y; Shimokawa T; Satoh T;
Gastric Cancer; 2020 May; 23(3):520-530. PubMed ID: 31667688
[TBL] [Abstract][Full Text] [Related]
6. Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy.
Cho JH; Lim JY; Cho JY
PLoS One; 2017; 12(10):e0186362. PubMed ID: 29040299
[TBL] [Abstract][Full Text] [Related]
7. Phase II feasibility study of adjuvant S-1 plus docetaxel for stage III gastric cancer patients after curative D2 gastrectomy.
Tamura S; Fujitani K; Kimura Y; Tsuji T; Matsuyama J; Iijima S; Imamura H; Inoue K; Kobayashi K; Kurokawa Y; Furukawa H;
Oncology; 2011; 80(5-6):296-300. PubMed ID: 21778769
[TBL] [Abstract][Full Text] [Related]
8. Systemic chemotherapy for gastric cancer with early recurrence after adjuvant S-1 monotherapy: a multicenter retrospective study.
Mitani S; Kadowaki S; Hasegawa H; Wakatsuki T; Hara H; Tajika M; Nishikawa K; Hirao M; Takahari D; Chin K; Muro K
Int J Clin Oncol; 2019 Oct; 24(10):1197-1203. PubMed ID: 31152323
[TBL] [Abstract][Full Text] [Related]
9. Risk Factors for Poor Compliance with Adjuvant S-1 Chemotherapy for Gastric Cancer: A Multicenter Retrospective Study.
Yamashita K; Kurokawa Y; Yamamoto K; Hirota M; Kawabata R; Mikami J; Masuzawa T; Takiguchi S; Mori M; Doki Y
Ann Surg Oncol; 2017 Sep; 24(9):2639-2645. PubMed ID: 28608116
[TBL] [Abstract][Full Text] [Related]
10. Feasibility study of alternate-day S-1 as adjuvant chemotherapy for gastric cancer: a randomized controlled trial.
Tatebe S; Tsujitani S; Nakamura S; Shimizu T; Yamane N; Nishidoi H; Kurisu Y; Kanayama H; Ogawa H; Ikeguchi M
Gastric Cancer; 2014; 17(3):508-13. PubMed ID: 23948997
[TBL] [Abstract][Full Text] [Related]
11. Timing and site-specific trends of recurrence in patients with pathological stage II or III gastric cancer after curative gastrectomy followed by adjuvant S-1 monotherapy.
Takahashi R; Ohashi M; Kano Y; Ida S; Kumagai K; Nunobe S; Chin K; Yamaguchi K; Nagino M; Sano T; Hiki N
Gastric Cancer; 2019 Nov; 22(6):1256-1262. PubMed ID: 30877407
[TBL] [Abstract][Full Text] [Related]
12. Treatment using oxaliplatin and S-1 adjuvant chemotherapy for pathological stage III gastric cancer: a multicenter phase II study (TOSA trial) protocol.
Namikawa T; Maeda H; Kitagawa H; Oba K; Tsuji A; Yoshikawa T; Kobayashi M; Hanazaki K
BMC Cancer; 2018 Feb; 18(1):186. PubMed ID: 29439671
[TBL] [Abstract][Full Text] [Related]
13. A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for stage III/IV gastric cancer (CCOG 1106).
Kurimoto K; Ishigure K; Mochizuki Y; Ishiyama A; Matsui T; Ito S; Nakayama H; Tanaka N; Kobayashi D; Sakamoto J; Nakao A; Kodera Y
Gastric Cancer; 2015 Apr; 18(2):354-9. PubMed ID: 24838732
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study of adjuvant chemotherapy with S-1 plus cisplatin for gastric cancer.
Takahari D; Hamaguchi T; Yoshimura K; Katai H; Ito S; Fuse N; Kinoshita T; Yasui H; Terashima M; Goto M; Tanigawa N; Shirao K; Sano T; Sasako M
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1423-8. PubMed ID: 20809123
[TBL] [Abstract][Full Text] [Related]
15. [A safety analysis in patients treated with oxaliplatin plus S-1 as adjuvant therapy for gastric cancer].
Zhou Y; Huang J; Yang L; Chi Y; Qu T; Lü X; Wang JW
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):860-4. PubMed ID: 23291138
[TBL] [Abstract][Full Text] [Related]
16. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial.
Tsuburaya A; Yoshida K; Kobayashi M; Yoshino S; Takahashi M; Takiguchi N; Tanabe K; Takahashi N; Imamura H; Tatsumoto N; Hara A; Nishikawa K; Fukushima R; Nozaki I; Kojima H; Miyashita Y; Oba K; Buyse M; Morita S; Sakamoto J
Lancet Oncol; 2014 Jul; 15(8):886-93. PubMed ID: 24954805
[TBL] [Abstract][Full Text] [Related]
17. Proposal of a Scoring Scale to Estimate Risk of the Discontinuation of S-1 Adjuvant Monotherapy in Patients with Stage II to III Gastric Cancer: A Multi-Institutional Dataset Analysis.
Iizuka A; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
World J Surg; 2019 Aug; 43(8):2016-2024. PubMed ID: 30737551
[TBL] [Abstract][Full Text] [Related]
18. A two centers study of postoperative adjuvant chemotherapy with S-1 versus SOX/XELOX regimens for gastric cancer after D2 resection: a cohort study.
Zheng S; Zhou Y; Sun Y; Wang Z; Lu Y
Cancer Chemother Pharmacol; 2019 Oct; 84(4):819-827. PubMed ID: 31388724
[TBL] [Abstract][Full Text] [Related]
19. Delay in initiation of postoperative adjuvant chemotherapy with S-1 monotherapy and prognosis for gastric cancer patients: analysis of a multi-institutional dataset.
Nakanishi K; Kanda M; Ito S; Mochizuki Y; Teramoto H; Ishigure K; Murai T; Asada T; Ishiyama A; Matsushita H; Tanaka C; Kobayashi D; Fujiwara M; Murotani K; Kodera Y
Gastric Cancer; 2019 Nov; 22(6):1215-1225. PubMed ID: 30955110
[TBL] [Abstract][Full Text] [Related]
20. [Adjuvant chemotherapy with S-1 plus docetaxel for highly advanced gastric cancer patients].
Egawa T; Kemmochi T; Irino T; Mihara K; Okamura A; Etoh E; Inaba Y; Segami K; Ito Y; Nagashima A
Gan To Kagaku Ryoho; 2012 Nov; 39(12):2310-2. PubMed ID: 23268060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
